Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 274

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 274
---
FOR” EACH OF THE DIRECTOR NOMINEES NAMED ABOVE.

135</div>

TABLE OF CONTENTS

#### PROPOSAL NO. 7 — THE ADJOURNMENT PROPOSAL
The Adjournment Proposal, if adopted, will approve the chairman’s adjournment of the Special Meeting to a later date to permit further solicitation of proxies. The Adjournment Proposal will only be presented to our stockholders in the event, based on the tabulated votes, there are not sufficient votes received at the time of the Special Meeting to approve the Business Combination Proposal or any of the other proposals herein.

Consequences if the Adjournment Proposal is Not Approved

If the Adjournment Proposal is not approved by our stockholders, the chairman will not adjourn the Special Meeting to a later date in the event, based on the tabulated votes, there are not sufficient votes received at the time of the Special Meeting to approve the Business Combination Proposal or any of the other proposals herein.

#### Vote Required for Approval
Assuming that a quorum is present at the Special Meeting, the affirmative vote of a majority of the total votes cast by the stockholders present and in person or represented by proxy at the Special Meeting and entitled to vote thereon is required to approve the Adjournment Proposal. An abstention will be counted towards the quorum requirement but will not count as a vote cast at the Special Meeting. A broker non-vote will neither be counted towards the quorum requirement (as we believe the Adjournment Proposal will be considered as non-discretionary) nor count as a vote cast in the Special Meeting.

The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus.

#### Recommendation of the Iris Board

### THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT
<div align='center'>IRIS STOCKHOLDERS VOTE “FOR” THE ADJOURNMENT PROPOSAL.

136</div>

TABLE OF CONTENTS

### SHARES ELIGIBLE FOR FUTURE SALE
Upon completion of the Business Combination, ParentCo will have 500,000,000 shares of ParentCo Common Stock authorized and, based on the assumptions set out elsewhere in this proxy statement/ prospectus, up to 26,774,477 shares of ParentCo Common Stock issued and outstanding. Subject to the Amended and Restated Registration Rights Agreement and Lock-up Agreement discussed below, all of the shares of Parent